SEC Form SC 13G filed by Karyopharm Therapeutics Inc.

$KPTI
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $KPTI alert in real time by email
SC 13G 1 formsc13g.htm

 

 

 

United States

Securities and Exchange Commission

Washington, D.C. 20549

 

Schedule 13G

 

(Rule 13d-102)

 


Information to be Included in Statements Filed Pursuant

to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

Pursuant to § 240.13d-2

 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

(Amendment No. )*

 

Karyopharm Therapeutics Inc.

(Name of Issuer)

 

Common Stock

(Title of Class of Securities)

 

48576U106

(CUSIP Number)

 

May 13, 2024

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 48576U106

Schedule 13G

Page 1 of 6

 

1

Names of Reporting Persons

J. Wood Capital Advisors LLC 

2

Check the Appropriate Box if a Member of a Group

(a) ☐
(b) ☐

3

SEC Use Only

 

4

Citizenship or Place of Organization

 

California 

Number of Shares Beneficially Owned by Each Reporting Person With 5

Sole Voting Power

6

Shared Voting Power

6,872,027 

7

Sole Dispositive Power

0

8

Shared Dispositive Power

 

6,872,027

9

Aggregate Amount Beneficially Owned by Each Reporting Person

 

6,872,027

10

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11

Percent of Class Represented by Amount in Row 9

 

5.5%

12

Type of Reporting Person

OO (Limited Liability Company)

 

 

 

 

CUSIP No. 48576U106

Schedule 13G

Page 2 of 6

 

1

Names of Reporting Persons

Jason Wood 

2

Check the Appropriate Box if a Member of a Group

(a) ☐
(b) ☐

3

SEC Use Only

 

4

Citizenship or Place of Organization

 

United States 

Number of Shares Beneficially Owned by Each Reporting Person With 5

Sole Voting Power

 


6

Shared Voting Power

 


6,872,027 

7

Sole Dispositive Power

 


0

8

Shared Dispositive Power

 

6,872,027

9

Aggregate Amount Beneficially Owned by Each Reporting Person

 

6,872,027

10

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11

Percent of Class Represented by Amount in Row 9

 

5.5%

12 Type of Reporting Person

IN

 

 

 

 

CUSIP No. 48576U106

Schedule 13G

Page 3 of 6

 

ITEM 1.(a) Name of Issuer:
    
   Karyopharm Therapeutics Inc. (the “Issuer”)

 

(b)Address of Issuer’s Principal Executive Offices:
    
   85 Wells Avenue, 2nd Floor, Newton, MA 02459

 

ITEM 2.(a) Name of Person Filing:
    
   Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:
    
   J. Wood Capital Advisors LLC
   Jason Wood
    
 (b) Address or Principal Business Office:
    
   The principal business address of each of the Reporting Persons is 1820 Calistoga Road, Santa Rosa, CA 95404.
    
 (c) Citizenship of each Reporting Person is:
    
   J. Wood Capital Advisors LLC is organized under the laws of the state of California. Jason Wood is a citizen of the United States.
    
 (d) Title of Class of Securities:
    
   Common stock, $0.0001 par value (“Common Stock”)
    
 (e) CUSIP Number:
    
   48576U106

 

ITEM 3.  

 

  Not applicable.

 

 

 

 

CUSIP No. 48576U106

Schedule 13G

Page 4 of 6

 

ITEM 4. Ownership.

 

  (a-c)

 

The ownership information presented below represents beneficial ownership of the shares of Common Stock, based upon 124,608,532 shares of Common Stock outstanding as of May 13, 2024.

 

Reporting Person 

Amount

beneficially

owned

  

Percent

of class:

   Sole power to vote or to direct the vote:   Shared power to vote or to direct the vote:  

Sole power to dispose or to direct the disposition

of:

  

Shared

power to

dispose or

to direct

the

disposition

of:

 
J. Wood Capital Advisors LLC   6,872,027    5.5%    0    6,872,027    0    6,872,027 
Jason Wood   6,872,027    5.5%    0    6,872,027    0    6,872,027 

 

J. Wood Capital Advisors LLC is the record holder of the shares of Common Stock reported herein. Jason Wood is the managing member of J. Wood Capital Advisors LLC. As a result, Jason Wood may be deemed to share beneficial ownership of the shares of Common Stock directly held by J. Wood Capital Advisors LLC.

 

ITEM 5.Ownership of Five Percent or Less of a Class.

 

Not applicable.

 

ITEM 6.Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

ITEM 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable.

 

ITEM 8.Identification and Classification of Members of the Group.

 

Not applicable.

 

ITEM 9.Notice of Dissolution of Group.

 

Not applicable.

 

ITEM 10.Certification.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

 

 

 

 

CUSIP No. 48576U106

Schedule 13G

Page 5 of 6

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: May 23, 2024

J. Wood Capital Advisors LLC

   
  By: /s/ Jason Wood
  Name: Jason Wood
  Title: Managing Member
     
  Jason Wood
   
  /s/ Jason Wood

 

 

 

 

CUSIP No. 48576U106

Schedule 13G

Page 6 of 6

 

LIST OF EXHIBITS

 

Exhibit No.   Description
99   Joint Filing Agreement.

 

 

 

Get the next $KPTI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$KPTI

DatePrice TargetRatingAnalyst
1/19/2023$8.00Overweight
Piper Sandler
11/4/2022$7.00 → $10.00Sector Perform → Outperform
RBC Capital Mkts
3/8/2022$12.00 → $8.00Sector Perform
RBC Capital
3/2/2022$8.00 → $6.00Market Perform
SVB Leerink
2/9/2022$8.00Underweight → Neutral
JP Morgan
1/10/2022$6.00 → $8.00Market Perform
SVB Leerink
12/9/2021$8.00 → $9.00Sector Perform
RBC Capital
11/19/2021$27.00 → $10.00Overweight → Equal-Weight
Morgan Stanley
More analyst ratings

$KPTI
Press Releases

Fastest customizable press release news feed in the world

See more
  • Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEWTON, Mass., March 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 3,316 restricted stock units (RSUs) to five newly-hired employees. These RSU awards were granted as of February 28, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three

    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Karyopharm Announces 1-for-15 Reverse Stock Split

    NEWTON, Mass., Feb. 24, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will implement a 1-for-15 reverse stock split of the issued shares of the Company's common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on February 25, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Special Meeting of Stockholders held on January 30, 2025, with the final ratio subsequently determined by the Company's Board of Directors. One of the primary goals of the Reverse Stock Split is to increase the per-share market price of the Compa

    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

    – Total Revenue of $145 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $113 Million for Full Year 2024 – – Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Naïve Myelofibrosis Anticipated in 2H 2025; Company on Track to Complete Enrollment in 1H 2025 – – Company Announces Update to Phase 3 XPORT-EC-042 Trial of Selinexor as Maintenance Therapy in Advanced or Recurrent TP53 Wild-Type Endometrial Cancer. Following Dialogue with the FDA Regarding the Evolving Treatment Landscape, Trial to Focus Enrollment on Patients with Either pMMR Tumors or Patients with dMMR Tumors that are Medically Ineligible for Checkp

    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

$KPTI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$KPTI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$KPTI
SEC Filings

See more

$KPTI
Leadership Updates

Live Leadership Updates

See more
  • Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

    NEWTON, Mass., Jan. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025. In this role, Ms. Macomber will be responsible for leading and directing the financial activities of the Company. "Lori is an outstanding addition to the Karyopharm team," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "She brings extensive experience in strategic financial management and operations, which will be critical as we execute on our strategy to grow

    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

    NEWTON, Mass., Dec. 9, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications. "We are thrilled to have Brendan on board as we work towards delivering on and communicating important milestones for our organization in 2025," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "Brendan's experience as a former sell-side analyst, advisor to biopharmaceutical companies and proven ability to develop strong investor relations and corporate communications programs wi

    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

    NEWTON, Mass., Nov. 20, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Kristin Abate, the Company's Vice President, Accounting, Corporate Controller and Assistant Treasurer has been appointed the Company's Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024. Ms. Abate, who has also served as the Company's interim principal financial officer and interim principal accounting officer since November 6, 2024, has been designated as the Company's principal accounting officer, effective November 20, 2024. Ms. Abate will continue to serve as t

    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

$KPTI
Financials

Live finance-specific insights

See more
  • Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

    – Total Revenue of $145 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $113 Million for Full Year 2024 – – Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Naïve Myelofibrosis Anticipated in 2H 2025; Company on Track to Complete Enrollment in 1H 2025 – – Company Announces Update to Phase 3 XPORT-EC-042 Trial of Selinexor as Maintenance Therapy in Advanced or Recurrent TP53 Wild-Type Endometrial Cancer. Following Dialogue with the FDA Regarding the Evolving Treatment Landscape, Trial to Focus Enrollment on Patients with Either pMMR Tumors or Patients with dMMR Tumors that are Medically Ineligible for Checkp

    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

    -- Conference Call Scheduled for Wednesday, February 19, 2025, at 8:00 a.m. ET -- NEWTON, Mass., Feb. 12, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2024 financial results on Wednesday, February 19, 2025. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Wednesday, February 19, 2025, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask

    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

    – Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $29.5 Million; Continued Regulatory and Reimbursement Approvals Globally – – Following FDA Alignment, Absolute Change in Total Symptom Score (Abs-TSS) Will Replace TSS50 as a Co-Primary Endpoint in Phase 3 SENTRY Trial in JAKi Naïve Myelofibrosis (MF); Expected Top-line Data Read-out Remains on Track for 2H 2025 – – Narrows Full-Year 2024 Total Revenue Guidance Range to $145.0 Million to $155.0 Million; U.S. XPOVIO Net Product Revenue Guidance Range to $110.0 Million to $115.0 Million; R&D and SG&A Expense Guidance Range to $255.0 Million to $265.0 Million – NEWTON, Mass., Nov. 5,

    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

$KPTI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more